Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 112,572,336
  • Shares Outstanding, K 782,350
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.89
  • Price/Sales 10.02
  • Price/Cash Flow 23.88
  • Price/Book 13.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.39 +12.07%
on 08/24/17
144.59 -0.48%
on 09/21/17
+13.60 (+10.44%)
since 08/22/17
3-Month
126.86 +13.42%
on 08/21/17
144.59 -0.48%
on 09/21/17
+10.21 (+7.64%)
since 06/22/17
52-Week
96.93 +48.45%
on 10/25/16
144.59 -0.48%
on 09/21/17
+33.32 (+30.13%)
since 09/22/16

Most Recent Stories

More News
Juno Tenders $250M Follow-on Public Offering of Common Stock

Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.

CELG : 143.89 (+0.08%)
AZN : 33.95 (+3.47%)
ADRO : 10.80 (-1.82%)
JUNO : 45.14 (+8.46%)
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene

Top Research Reports for Northrop Grumman, BNY Mellon & Celgene

CELG : 143.89 (+0.08%)
NOC : 281.55 (+0.40%)
JNJ : 131.39 (-0.27%)
ANTM : 182.86 (-0.35%)
CL : 71.19 (-0.25%)
BK : 52.37 (-0.10%)
Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

CELG : 143.89 (+0.08%)
MRK : 65.13 (-0.72%)
ABBV : 87.48 (+0.08%)
RHHBY : 32.0200 (-0.06%)
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

CELG : 143.89 (+0.08%)
MRK : 65.13 (-0.72%)
RHHBY : 32.0200 (-0.06%)
BMY : 63.36 (+0.05%)
Companies to Watch as Biotech Makes a Comeback in 2017

This is a bull market, and some biotech stocks are the real raging bulls-especially when massive drug pipelines are at stake, and landmark FDA approvals shake things up with massive share price momentum....

CELG : 143.89 (+0.08%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
CALA : 15.90 (-1.85%)
KITE : 179.30 (-0.04%)
REGN : 432.72 (-0.17%)
CELGZ : 1.55 (+23.51%)
Little-Known Biotech Breakthrough Could Save Millions Of Lives

Someone dies of a stroke every 4 minutes in the United States. Globally, 15 million people suffer a stroke every year. It's debilitating physically and financially-but one little-known company has developed...

Q : 94.70 (+0.51%)
CELG : 143.89 (+0.08%)
CRBP : 6.85 (+4.58%)
XON : 18.75 (unch)
ABBV : 87.48 (+0.08%)
CELGZ : 1.55 (+23.51%)
Celgene (CELG) Fusion Program Studies Put on Hold by FDA

Celgene Corporation (CELG) announced that the FDA put a hold on several trials in the FUSION program evaluating Imfinzi, an anti-PD-L1 antibody, in combination with immunomodulatory and chemotherapy agents...

CELG : 143.89 (+0.08%)
AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
ADRO : 10.80 (-1.82%)
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus

With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.

CELG : 143.89 (+0.08%)
BLUE : 128.75 (+0.70%)
NVS : 86.16 (+1.44%)
ZIOP : 6.17 (+1.82%)
GILD : 83.27 (+0.79%)
KITE : 179.30 (-0.04%)
JUNO : 45.14 (+8.46%)
Your September Trading Playbook

This post Your September Trading Playbook appeared first on Daily Reckoning . Today Greg Guenthner reveals his favorite moves for September. He also shows you why reports of this bull market’s coming...

CELG : 143.89 (+0.08%)
WUBA : 66.78 (-0.15%)
BLUE : 128.75 (+0.70%)
BIDU : 240.57 (+0.69%)
INCY : 110.85 (-3.65%)
FCX : 14.06 (+0.57%)
JD : 42.37 (-1.42%)
XBI : 83.91 (-0.80%)
Celgene Provides Update on the Fusion(TM) Clinical Program

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial...

CELG : 143.89 (+0.08%)
CELGZ : 1.55 (+23.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Support & Resistance

2nd Resistance Point 145.72
1st Resistance Point 144.80
Last Price 143.89
1st Support Level 142.36
2nd Support Level 140.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.